These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 36136277

  • 1. Central nervous systemic efficacy of immune checkpoint inhibitors and concordance between intra/extracranial response in non-small cell lung cancer patients with brain metastasis.
    Kang S, Jeong H, Park JE, Kim HS, Kim YH, Lee DH, Kim SW, Lee JC, Choi CM, Yoon S.
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4523-4532. PubMed ID: 36136277
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China.
    Sheng J, Li H, Yu X, Yu S, Chen K, Pan G, Xie M, Li N, Zhou Z, Fan Y.
    Thorac Cancer; 2021 Nov; 12(22):3019-3031. PubMed ID: 34596346
    [Abstract] [Full Text] [Related]

  • 3. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
    Zheng MM, Tu HY, Yang JJ, Zhang XC, Zhou Q, Xu CR, Jiang BY, Yang XN, Yang XR, Deng JY, Yang MY, Xu BF, Chen XM, Li YS, Wu YL.
    Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
    [Abstract] [Full Text] [Related]

  • 4. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Li X, Wang L, Chen S, Zhou F, Zhao J, Zhao W, Su C.
    Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
    [Abstract] [Full Text] [Related]

  • 5. Predictive role of intracranial PD-L1 expression in a real-world cohort of NSCLC patients treated with immune checkpoint inhibition following brain metastasis resection.
    Wasilewski D, Onken J, Höricke P, Bukatz J, Murad S, Früh A, Shaked Z, Misch M, Kühl A, Klein O, Ehret F, Kaul D, Radbruch H, Capper D, Vajkoczy P, Horst D, Frost N, Bischoff P.
    J Neurooncol; 2024 Mar; 167(1):155-167. PubMed ID: 38358406
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.
    Zhou S, Ren F, Meng X.
    Front Immunol; 2022 Mar; 13():955944. PubMed ID: 36238280
    [Abstract] [Full Text] [Related]

  • 7. PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.
    Zhu Y, Zhang Y, Hu X, Wang M, Wang H, Liu Y.
    J Cancer Res Clin Oncol; 2022 Dec; 148(12):3557-3566. PubMed ID: 35857126
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Triple therapy boosts survival in NSCLC patients with brain metastases: a retrospective cohort study of chemotherapy, ICIs, and antiangiogenic agents.
    Yang D, Munai E, Zeng S, Tao D, Yuan Z, Du L, Zhou W, Wu Y, Zhu XD.
    Cancer Immunol Immunother; 2024 Sep 06; 73(11):226. PubMed ID: 39237636
    [Abstract] [Full Text] [Related]

  • 11. First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis.
    Hofstetter K, Taugner J, Käsmann L, Mansoorian S, Flörsch B, Eze C, Tufman A, Reinmuth N, Duell T, Belka C, Manapov F.
    Strahlenther Onkol; 2024 Jul 06; 200(7):614-623. PubMed ID: 37975883
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Intracranial activity of first-line immune checkpoint inhibitors combined with chemotherapy in advanced non-small cell lung cancer.
    Huang Z, Wu F, Xu Q, Song L, Zhang X, Wang Z, Deng L, Zhang Y, Zeng L, Yang N.
    Chin Med J (Engl); 2023 Jun 20; 136(12):1422-1429. PubMed ID: 37195128
    [Abstract] [Full Text] [Related]

  • 16. Factors related to rapid progression of non-small cell lung cancer in Chinese patients treated using single-agent immune checkpoint inhibitor treatment.
    Zhang L, Bai L, Liu X, Liu Y, Li S, Liu J, Zhang S, Yang C, Ren X, Cheng Y.
    Thorac Cancer; 2020 May 20; 11(5):1170-1179. PubMed ID: 32134200
    [Abstract] [Full Text] [Related]

  • 17. The efficacy of immune checkpoint inhibitors in advanced EGFR-Mutated non-small cell lung cancer after resistance to EGFR-TKIs: Real-World evidence from a multicenter retrospective study.
    Hu J, Huang D, Wang Y, Li D, Yang X, Fu Y, Du N, Zhao Y, Li X, Ma J, Hu Y.
    Front Immunol; 2022 May 20; 13():975246. PubMed ID: 36159795
    [Abstract] [Full Text] [Related]

  • 18. Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases.
    Enright TL, Witt JS, Burr AR, Yadav P, Leal T, Baschnagel AM.
    Clin Lung Cancer; 2021 Mar 20; 22(2):110-119. PubMed ID: 33281062
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.